Recent Updates
Recently added Catalysts

AZD1704

Phase 1

Pain | Small molecule | Pain |AstraZeneca PLC|Last Updated: Jun 24, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment80
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00692042Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704PHASE1 COMPLETED 80Mar 1, 2008Jun 1, 2008Jun 24, 20081 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To investigate the safety and tolerability of AZD1704 following single ascending doses in healthy volunteers.
At screening, during residential period (daily) and at follow-up
Secondary Endpoints
To investigate the subjective CNS effects of specific adjectives (stimulated, anxious, sedated, down and high) rated on visual analogue mood scale (VAMS).
During residential period (daily)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
Treatment Arms
ArmTypeDescription
1EXPERIMENTAL -
Interventions
NameTypeDescription
AZD1704DRUGOne dose, by mouth
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy volunteers, man or woman of non child-bearing potential * Provision of signed informed consent. Exclusion Criteria: * History of somatic disease/condition that may interfere with the objectives ot the study, as judged by the Investigator. History of seizures, with th...

Countries:United Kingdom
Unlock Eligibility Criteria